[1]Andrikou K, Rossi T, Verlicchi A, et al. Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer[J]. Int J Mol Sci. 2023 Nov 8;24(22):16085.[2]Andree KC, van Dalum G, Terstappen LW. Challenges in circulating tumor cell detection by the CellSearch system[J]. Mol Oncol. 2016 Mar;10(3):395-407.[3]Lindsay C.R, Faugeroux V, Michiels S, et al. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups[J]. Ann. Oncol. 2017;28:1523–1531.[4]Ntzifa A, Strati A, Kallergi G, et al. Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients[J]. Sci Rep. 2021 Jan 27;11(1):2313.[5]Park, NY. Kim, J. Kim, et al,. Concordances assessment between MET-positive circulating tumour cells and disease progression in patients with EGFR mutated NSCLC. 2024, ESMO, 1268P.[6]Spina A, De Pasquale V, Cerulo G, et al. HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation[J]. Biomedicines 2015 Jan 22;3(1):71-88.[7]Chang Y, Wang Y, Li B, et al. Whole-Exome Sequencing on Circulating Tumor Cells Explores Platinum-Drug Resistance Mutations in Advanced Non-small Cell Lung Cancer[J]. Front Genet. 2021 Sep 20;12:722078.[8]Pailler E, Faugeroux V, Oulhen M, et al. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer[J]. Clin Cancer Res. 2019 Nov 15;25(22):6671-6682.
